隨著中醫(yī)藥治療在新型冠狀病毒肺炎（COVID-19）疫情防控中的廣泛使用和不斷推進(jìn)，中醫(yī)藥對(duì)COVID-19的防治取得了許多創(chuàng)新成果。及時(shí)把相關(guān)創(chuàng)新成果的專利信息進(jìn)行梳理和分析，一方面有利于科研工作者更快速地利用專利情報(bào)挖掘和篩選更有效的藥物，另一方面也有助于啟發(fā)研發(fā)人員加強(qiáng)創(chuàng)新成果的專利保護(hù)。以國(guó)家衛(wèi)生健康委員會(huì)發(fā)布的《新型冠狀病毒肺炎診療方案（試行第六版）》為主線，對(duì)用于醫(yī)學(xué)觀察期的推薦中成藥以及用于臨床治療期的基礎(chǔ)方劑、推薦處方和推薦中成藥的相關(guān)專利信息進(jìn)行梳理分析，闡述推薦處方和推薦中成藥的專利技術(shù)路線，并進(jìn)行重點(diǎn)專利信息分析，試圖為中醫(yī)藥科研工作提供有益參考。

With the wide application and constantly advancing of traditional Chinese medicine(TCM) in the prevention and control of COVID-19, many innovative achievements have been made in the prevention and treatment of COVID-19 by TCM. Analyzing the patent information of related innovations timely will not only help researcher to use patent information more quickly to mine and screen more effective drugs, but also help inspiring R&D personnel to strengthen patent protection for innovations. This article is based on Chinese Clinical Guidance for COVID-19 Diagnosis and Treatment (6th edition) published by National Health Commitssion of the People's Republic of China, analyses related patent information on recommended Chinese patent medicines in medical observation period, and basic prescriptions, recommended prescriptions and recommended Chinese patent medicines in clinical treatment period, describes the patent technology roadmap of recommended prescriptions and recommended Chinese patent medicines, analyzes key patent information, and tries to provide useful reference for scientific research of TCM.

R288